Ludwig Boltzmann Institute for Cancer Research/
Institute of Pharmacology
Währingerstrasse 13A
1090 Vienna
Austria
dagmar.stoiber@meduniwien.ac.at
http://www.lbicr.lbg.ac.at
Our laboratory is generating new mouse models to study haematopoietic malignancies. We focus on investigating leukaemia and lymphoma development as well as the interaction of the immune system with the evolving tumour. The experimental strategies to address our research interests include biochemical and molecular biological approaches, mouse molecular genetics tools and retroviral-mediated gene transduction into haematopoietic stem cells.
For all projects we use flow cytometry, molecular biological and biochemical techniques and mouse genetics.
Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, Gotthardt D, Warsch W, Eckelhart E, Kantner HP, Kalinke U, Lienenklaus S, Weiss S, Strobl B, Müller M, Sexl V, Stoiber D. (2012) Conditional IFNAR1 ablation reveals distinct requirements of type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology. 1(7)
Schuster C, Berger A, Hoelzl MA, Putz EM, Frenzel A, Simma O, Moritz N, Hoelbl A, Kovacic B, Freissmuth M, Müller M, Villunger A, Müllauer L, Schmatz AI, Streubel B, Porpaczy E, Jäger U, Stoiber D*, Sexl V.* (2011) The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas. Blood. 118(17):4635-45. Epub 2011 Aug 30.
Simma O, Zebedin E, Neugebauer N, Schellack C, Pilz A, Chang-Rodriguez S, Lingnau K, Weisz E, Putz EM, Pickl WF, Felzmann T, Müller M, Decker T, Sexl V, Stoiber D. (2009) Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. Cancer Res. 69(1):203-11.
Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, Weisz E, Artwohl M, Kleine OC, Muller M, Baumgartner-Parzer S, Ghysdael J, Freissmuth M, Sexl V. (2004) TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest. 114(11):1650-8.